European journal of pharmacologyLeukemiaMyeloidAcuteHumansCytarabine
Synergistic effects between CD36 monoclonal antibody and cytarabine for treatment of AML.
Shuxin Huang, Dawei Chen, Yalin Luo, Xiuzhang Xu, Shengxue Luo, Hui Ren, Wenjie Xia, Xin Ye, Caixia Wang, Cunte Chen, Bowen Fu, Sentot Santoso, Tingting Li, Huaqin Liang, Yongshui Fu
Published: 202610.1016/j.ejphar.2025.178478
Abstract
Acute myeloid leukemia (AML) is a clinically aggressive and genetically heterogeneous hematologic malignancy with persistently poor clinical outcomes, largely due to the resistance to conventional chemotherapeutic agents including cytarabine (Ara-C).…
Preview only. Read the full abstract at the source